Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain
ConditionHerpes Zoster
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute/subacute zoster-associated pain (ZAP) patients.
Eligibility criteria
Qualifiers
Ages more than 18 years;
Patients with onset of herpes zoster (HZ) rash less than 90 days;
HZ affected the spinal nerves (cervical/thoracic/lumbar nerve);
Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)；
Disqualifiers
Obstructive sleep apnoea syndrome;
Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
A history of systemic immune diseases, organ transplantation, or cancers;
A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
Trial design
Treatments tested in this trial
- esketamine group
- PRF group
Treatment groups
184 Participants
are divided into 2 treatment groupsSponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Beijing Xiaotangshan Hospital
Collaborator
The First Hospital of Fangshan District,Beijing
Collaborator
Beijing Ditan Hospital
Collaborator
Hengshui People's Hospital
Collaborator
Source ClinicalTrials.gov